Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FDA Adverse Event Reporting System (FAERS) )
Authors' conclusion
GLP-1RAs are linked to a broad range of AEs across indications.
Study context
- Population
- FAERS reports, 2012–2025137,451 GLP-1RA reports
- Exposure
- GLP-1 RAs vs other drugs
- GLP-1RAsn = 137,451
- Outcome
- Spectrum and frequency of AEs linked to GLP-1 RAs
Methodological detailsdisproportionality analysis of FAERS reports, disproportionality analyses, subgroup analyses by indication, vs other drugs and by individual GLP-1 RA, Open-access AE exploration portal developed (http://glp1.tanlab.org)
- Disproportionality analysis of FAERS reports
- Disproportionality analyses
- Subgroup analyses by indication, vs other drugs and by individual GLP-1 RA
- Open-access AE exploration portal developed (http://glp1.tanlab.org)
Main finding
As reported in the abstract
AEs linked to GLP-1 RAs
- Most frequent adverse events (AEs): gastrointestinal, nutritional and metabolic, and psychiatric disorders, at higher rates than with other drugs
Observational data: associations, not effects.
Further findings
AEs in diabetes use
- GLP-1 RAs associated with retinopathy, hearing loss and cataracts
AEs in weight management/obesity use
- Nutritional, metabolic and psychiatric AEs predominated
Original publication
Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FAERS ). Obesity (Silver Spring). Published 9 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →